Nasri Peiman, Saeidi Shima, Saneian Hosein, Famouri Fatemeh, Sadeghi Somayeh, Kashani Leila Mohammad Taghizadeh, Khademian Majid
Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Child Growth and Development Research Center, Research Institute for Primordial Prevention of Noncommunicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Pharm Pract. 2022 May 25;10(4):180-184. doi: 10.4103/jrpp.jrpp_57_21. eCollection 2021 Oct-Dec.
This study aimed to compare the LaxaPlus Barij and polyethylene glycol (4000) in pediatric (children 2-15 years old) functional constipation.
The present study is a randomized clinical trial. The study population included patients with functional constipation aged 2-15 years who were referred to the gastrointestinal clinic of Imam Hossein hospital in Isfahan in 2019. Patients were randomly assigned into two treatment groups. Data analysis was performed using SPSS software. The significance level in the present study is considered <0.05.
Sixty children with functional constipation were selected based on the inclusion and exclusion criteria in this study. The present study results showed no significant difference between demographic characteristics, including age, weight, and gender of children with constipation in the two groups ( > 0.05). The present study results showed that both groups' mean stool consistency and the number of bowel movements increased significantly after the intervention ( < 0.05). However, the number of bowel movements in the first group was significantly higher than in the second group ( < 0.05).
The present study results showed that both drugs effectively treat children with functional constipation. However, after 8 weeks of intervention, the frequency of bowel movements, pain intensity, and abdominal pain in the group LaxaPlus Barij was more effective. However, the level of satisfaction did not differ significantly between the two groups.
本研究旨在比较LaxaPlus Barij与聚乙二醇（4000）治疗小儿（2至15岁）功能性便秘的效果。
本研究为一项随机临床试验。研究对象包括2019年转诊至伊斯法罕伊玛目侯赛因医院胃肠科的2至15岁功能性便秘患者。患者被随机分为两个治疗组。使用SPSS软件进行数据分析。本研究的显著性水平设定为<0.05。
根据本研究的纳入和排除标准，选取了60名功能性便秘儿童。本研究结果显示，两组便秘儿童的人口统计学特征，包括年龄、体重和性别，均无显著差异（>0.05）。本研究结果表明，干预后两组的平均大便稠度和排便次数均显著增加（<0.05）。然而，第一组的排便次数显著高于第二组（<0.05）。
本研究结果表明，两种药物均能有效治疗小儿功能性便秘。然而，经过8周的干预后，LaxaPlus Barij组的排便频率、疼痛强度和腹痛情况更为有效。然而，两组之间的满意度水平无显著差异。
